Division of Gastroenterology and Hepatology, Oregon Health and Science University, Portland Oregon.
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Clin Gastroenterol Hepatol. 2024 May;22(5):944-955. doi: 10.1016/j.cgh.2024.01.050. Epub 2024 Feb 28.
Despite incredible growth in systems of care and rapidly expanding therapeutic options for people with inflammatory bowel disease, there are significant barriers that prevent patients from benefiting from these advances. These barriers include restrictions in the form of prior authorization, step therapy, and prescription drug coverage. Furthermore, inadequate use of multidisciplinary care and inflammatory bowel disease specialists limits patient access to high-quality care, particularly for medically vulnerable populations. However, there are opportunities to improve access to high-quality, patient-centered care. This position statement outlines the policy and advocacy goals that the American Gastroenterological Association will prioritize for collaborative efforts with patients, providers, and payors.
尽管针对炎症性肠病患者的医疗护理体系有了令人难以置信的发展，治疗方案也在迅速扩大，但仍存在许多障碍，使患者无法从这些进步中受益。这些障碍包括事先授权、分步治疗和处方药覆盖范围等形式的限制。此外，多学科护理和炎症性肠病专家的使用不足限制了患者获得高质量护理的机会，特别是对医疗脆弱人群而言。然而，仍有机会改善获得高质量以患者为中心的护理的途径。本立场声明概述了美国胃肠病学协会将与患者、提供者和支付方合作的重点优先政策和宣传目标。
